Category: Medical Breakthroughs

Can early and high intravenous dose of vitamin C prevent and treat Coronavirus 2019 (COVID-19)?

Vitamin C is not a patented drug and so is low cost. The use of Vitamin C as a treatment protocol for Coronavirus infections is rarely mentioned in the main news media. When one gets sick, Vitamin C  in your body is depleted.

There were initial reports out of China that Coronavirus patients were being given intravenous Vitamin C. Vitamin C is also know to help patients who get Sepsis, which can also be the result of acquiring Coronavirus.

Some New York Hospitals have also treated Coronavirus patients with intravenous Vitamin C.

A new report has been published by Medicine in Drug Discovery, a peer reviewed journal by Elsevier, which details treating Coronavirus Patients using intravenous Vitamin C.

Click on the report title link below to visit the Elsevier’s Medicine in Drug Discovery site to read the report:

Can early and high intravenous dose of vitamin C prevent and treat Coronavirus disease 2019 (COVID-19)?

The report is as follows courtesy of Elsevier and Medicine in Drug Discovery:

Author links open overlay panel Richard Z.Cheng

Under a Creative Commons license
open access

The COVID-19 (SARS-2-Cov) pandemic, first reported in Wuhan, China, is now spreading to many continents and countries, causing a severe public health burden. Currently, there is no vaccine or specific antiviral drug for this deadly disease. A quick, deployable and accessible, effective and safe treatment is urgently needed to save lives and curtail the spreading. Acute respiratory distress syndrome (ARDS) is a key factor of fatality. Significantly increased oxidative stress due to rapid release of free radicals and cytokines is the hallmark of ARDS which leads to cellular injury, organ failure and death. Early use of large dose antioxidants, such as vitamin C (VC) may become an effective treatment for these patients. Clinical studies also show that high-dose oral VC provides certain protection against viral infection. Neither intravenous nor oral administration of high-dose VC is associated with significant side effects. Therefore, this regimen should be included in the treatment of COVID-19 and used as a preventative measure for susceptible populations such as healthcare workers with higher exposure risks.

Coronaviruses and influenza are among the pandemic viruses that can cause lethal lung injuries and death from ARDS [[1], [2], [3]]. Viral infections could evoke “cytokine storm” that leads to lung capillary endothelial cell activation, neutrophil infiltration and increased oxidative stress (reactive oxygen and nitrogen species). ARDS, characteristic of severe hypoxemia, is usually accompanied by uncontrolled inflammation, oxidative injury and damage to the alveolar-capillary barrier [4]. Increased oxidative stress is a major insult in pulmonary injury including acute lung injury (ALI) and ARDS, two clinical manifestations of acute respiratory failure with substantially high morbidity and mortality [5,6].

In a report of 29 patients with COVID-19 pneumonia, 27 (93%) showed increased hsCRP, a marker of inflammation and oxidative stress [7]. Transcription factor, nuclear factor erythroid 2 (nfe2)-related factor 2 (nrf2), is a major regulator of antioxidant response element (ARE)-driven cytoprotective protein expression. Activation of Nrf2 signaling plays an essential role in preventing cells and tissues from injury induced by oxidative stress. VC, an important component of the cellular antioxidant system [8], is beneficial to critical care management [9]. Cytokine storm is observed in both viral and bacterial infections [3] and results in increased oxidative stress via a common and non-specific pathway. Since the prevention and management of oxidative stress could be realized by large dose of antioxidants, this approach may be applicable to COVID-19 with intravenous high-dose VC based on the outcome of three previous clinical studies involving a total of 146 patients with sepsis [10].

Hemila and colleagues reported that various high-dose intravenous VC infusions (e.g., 200 mg/kg body weight/day, divided into 4 doses) shortened the intensive care unit (ICU) stay by 97.8% [11], accompanied by a significant reduction in the mortality rate [12]. Such an experience was reproduced among patients ill with severe influenza [13,14]. Indeed, dietary antioxidants (VC and sulforaphane) were shown to decrease oxidative stress induced acute inflammatory lung injury in patients receiving mechanical ventilation [15]. In addition, oral VC (e.g., 6 g daily) was able to reduce viral infection risk [16] or to improve symptoms [17].

High-dose intravenous VC has also been successfully used in the treatment of 50 moderate to severe COVID-19 patients in China. The doses used varied between 2 g and 10 g per day, given over a period of 8–10 h. Additional VC bolus may be required among patients in critical conditions. The oxygenation index was improving in real time and all the patients eventually cured and were discharged [18]. In fact, high-dose VC has been clinically used for several decades and a recent NIH expert panel document states clearly that this regimen (1.5 g/kg body weight) is safe and without major adverse events [19].

Because the development of efficacious vaccines and antiviral drugs takes time, VC and other antioxidants are among currently available agents to mitigate COVID-19 associated ARDS. Given the fact that high-dose VC is safe, healthcare professionals should take a close look at this opportunity. Obviously, well-designed clinical studies are absolutely needed to develop standard protocols for bedside use.

References

© 2020 Published by Elsevier B.V.
Posted at Uniquely Toronto by Vincent Banial
Advertisement

Using Brewer’s Yeast to produce Marijuana’s main ingredients : mind-altering THC and non-psychoactive CBD

You no longer need to grow a Marijuana plant to extract THC and CBD. You can get both by using Brewer’s Yeast and Sugar. You also get purer products. For example you can make CBD without the worry of it also containing THC.

This is revolutionary. It could eliminate huge Marijuana plant grow operations. It could also produce Cannabinoids which cannot be obtained from Marijuana plants. The consistency and purity of the produced product can be regulated to be uniform from batch to batch. This new process offers great potential in finding, via Medical Research Studies, new medical benefits of THC, CBD and other Cannabinoids.

Cristina Sánchez has been studying Cannabis for fifteen years  at Complutense University in Madrid Spain.  She has discovered that THC from Cannabis can kill Cancer cells.

Dr Christina Sanchez explains how cannabis kills cancer cell from Life With Cannabis on Vimeo.

Being able to produce Medical Cannabis products like THC in a pure form using Brewer’s Yeast opens up a lot of potential in the Medical field as you can maintain purity and quality  in each batch produced. For example, there have been documented  cases of patients who have seizures and are helped by CBD. You also eliminate the potential use of Pesticides in Plant Grow Operations.

Click on this link to visit the ScienceDaily website to read the newly published research from the University of California – Berkeley: “Yeast produce low-cost, high-quality cannabinoids.” ScienceDaily. ScienceDaily, 27 February 2019. <www.sciencedaily.com/releases/2019/02/190227131838.htm>.

Click on this link to visit the website of the journal Nature and read the abstract of the February 27 2019 published research article titled: “Complete biosynthesis of cannabinoids and their unnatural analogues in yeast“.

Click on this link to visit the ScienceDaily website to read the research report titled: “Benefits of medical marijuana for treatment of epilepsy examined“

Click on this link to visit the Bloomberg website to read their page about Demetrix Inc.

The information provided about cannabis is for informational purposes only. Please consult your physician before making any medical decisions.

Posted by Vincent Banial

Harvard University discussion on the latest Scientific Findings about Medical Cannabis

Harvard University brought together researchers studying Marijuana’s health impacts with policymakers who are working to implement new laws in ways that will benefit and protect public health.

Video courtesy of the Harvard University YouTube channel

Click on this link to visit the National Cancer Institute website.

The following is from the National Cancer Institute webpage linked to above titled “Cannabis and Cannabinoids (PDQ®)–Patient Version
Questions and Answers About Cannabis”

Have any preclinical (laboratory or animal) studies been conducted using Cannabis or cannabinoids?

Preclinical studies of cannabinoids have investigated the following:

Antitumor activity

Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells.

A study in mice showed that cannabinoids may protect against inflammation of the colon and may have potential in reducing the risk of colon cancer, and possibly in its treatment.

A laboratory study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells and breast cancer cells.

A laboratory study of cannabidiol (CBD) in estrogen receptor positive and estrogen receptor negative breast cancer cells showed that it caused cancer cell death while having little effect on normal breast cells. Studies in mouse models of metastatic breast cancer showed that cannabinoids may lessen the growth, number, and spread of tumors.

A review of 34 studies of cannabinoids in glioma tumor models found that all but one study showed that cannabinoids can kill cancer cells without harming normal cells.
A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.

 

Posted by: Vincent Banial

Dr. Uma V Dhanabalan MD MPH FAAFP speaks at the South Carolina Statehouse about Medical Cannabis as being a treatment Option for many illnesses


Dr. Uma V Dhanabalan MD MPH FAAFP speaks at the South Carolina Statehouse about Medical Cannabis as being a treatment Option for many illnesses.


She speaks from first hand experience seeing her patients health improve after treatment with Medical Cannabis

Note: This video’se volume level is really low and you may need headphones or external speakers

Video is courtesy of SC Compassionate Care Alliance YouTube channel

 

How Cannabis kills Cancer Cells by Dr, Christina Sanchez

How Cannabis kills Cancer Cells

by Dr, Christina Sanchez

Video is courtesy of the Lincoln Horsley YouTube channel

“Cannabis has been shown to kill cancer cells in the laboratory ” posted by the National Cancer Institue at cancer.gov

Something which has apparently been known in Cancer Research circles, has been formally announced to the public.

“Cannabis has been shown to kill cancer cells in the laboratory” posted by the National Cancer Institue at cancer.gov

Photo of a Marijuana / Cannabis plantPhoto courtesy of the United States Fish and Wildlife Service

The info  below is from the website of the National Cancer Institute (https://www.cancer.gov)

Cannabis and Cannabinoids (PDQ®)–Patient Version

Go to Health Professional VersionPinterest

Sections

Overview

  • Cannabis , also known as marijuana, is a plant grown in many parts of the world which produces a resin containing compounds called cannabinoids. Some cannabinoids are psychoactive (acting on the brain and changing mood or consciousness) (see Question 1).
  • The use of Cannabis for medicinal purposes dates back to ancient times (see Question 3).
  • By federal law, the possession of Cannabis is illegal in the United States outside of approved research settings. However, a growing number of states, territories, and the District of Columbia have enacted laws to legalize medical marijuana (see Question 1).
  • In the United States, Cannabis is a controlled substance requiring special licensing for its use (see Question 1 and Question 3).
  • Cannabinoids are active chemicals in Cannabis that cause drug -like effects throughout the body, including the central nervous system and the immune system (see Question 2).
  • The main active cannabinoid in Cannabis is delta-9-THC. Another active cannabinoid is cannabidiol (CBD), which may relieve pain, lower inflammation, and decrease anxiety without causing the “high” of delta-9-THC (see Question 2).
  • Cannabinoids can be taken by mouth, inhaled, or sprayed under the tongue (see Question 5).
  • Cannabis and cannabinoids have been studied in the laboratory and the clinic for relief of pain, nausea and vomiting, anxiety, and loss of appetite (see Question 6 and Question 7).
  • Cannabis and cannabinoids may have benefits in treating the symptoms of cancer or the side effects of cancer therapies. There is growing interest in treating children for symptoms such as nausea with Cannabis and cannabinoids, although studies are limited (see Question 7).
  • Two cannabinoids (dronabinol and nabilone) are drugs approved by the U.S. Food and Drug Administration (FDA) for the prevention or treatment of chemotherapy -related nausea and vomiting (see Question 7 and Question 10).
  • Cannabis has been shown to kill cancer cells in the laboratory (see Question 6).
  • At this time, there is not enough evidence to recommend that patients inhale or ingest Cannabis as a treatment for cancer-related symptoms or side effects of cancer therapy (see Question 7).
  • Cannabis is not approved by the FDA for use as a cancer treatment (see Question 9).

                           ******* end of post from cancer.gov *******

The following are additional links with info related to Cannabis and THC being able to kill Cancer Cells:

Antineoplastic Activity of Cannabinoids
http://www.ukcia.org/research/Antineo…

Cannabinoid Receptor Ligands Mediate Growth Inhibition & Cell Death In Mantle Cell Lymphoma
http://onlinelibrary.wiley.com/doi/10…

Δ9-Tetrahydrocannabinol Induces Apoptosis in Human Prostate PC-3 Cells via a Receptor-Independent Mechanism
http://onlinelibrary.wiley.com/doi/10…

Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma
http://jpet.aspetjournals.org/content…

Cannabinoid Receptors As Novel Targets for the Treatment of Melanoma
http://bbml.ucm.es/cannabis/archivos/…

DEA Eliminates 48-Year-Old Monopoly on Research-Grade Marijuana, Clearing Pathway for FDA Approval and Rescheduling

Cannabis plants
Photo of Cannabis plants courtesy of A7nubis and commons.wikimedia.org

Note from Vince: This is am extremely important change as the Cannabis grown by NIDA is an uncommon variety and apparently low in THC.  The FDA could approve a Medical Study of the use of high THC Cannabis in the treatment of Cancer, but NIDA always had the final word. If they approved a medical study (their usual common response was “No”) the study had to use the NIDA supplied Cannabis variety.

WASHINGTON, D.C. — Today, the Drug Enforcement Administration (DEA) announced their intention to grant licenses to additional marijuana growers for research, thereby ending the DEA-imposed 48-year monopoly on federally legal marijuana.  Since 1968, the University of Mississippi, under contract to the National Institute on Drug Abuse (NIDA), has maintained the only facility in the United States with federal permission to grow marijuana for research.

“It’s a complete and total end of the NIDA monopoly! There has been no production monopoly on any other Schedule I substance, like MDMA or LSD—only the cannabis plant. Licensing non-government cannabis producers, and thereby creating a path to FDA approval, will finally facilitate the removal of marijuana from Schedule I, and ultimately allow patients to receive insurance coverage for medical marijuana,” said Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

MAPS has been working to eliminate this cannabis research blockade since 1999. NIDA’s marijuana is eligible for research, but cannot be sold as a prescription medicine, making it unacceptable to the Food and Drug Administration (FDA) for use in future Phase 3 studies.  Ending the monopoly finally allows for a pathway to FDA approval for marijuana, which would thereby trigger rescheduling.

In 2001, MAPS partnered with University of Massachusetts-Amherst Professor Lyle Craker, Ph.D., to apply for a DEA license and end the monopoly. In 2007, after years of bureaucratic delays and lengthy legal hearings, a DEA Administrative Law Judge (ALJ) recommended that it would be in the public’s interest to grant Craker the license. In 2009, after almost two more years of delays and less than a week before the inauguration of President Obama, former DEA Administrator Michelle Leonhart rejected the ALJ recommendation. In 2011, Craker sued the DEA in the U.S. First Circuit Court of Appeals. In its 2013 decision, the Court uncritically accepted the DEA’s arguments that NIDA’s monopoly provided “an adequate supply produced under adequately competitive conditions.”

Since the 2013 decision, Craker’s argument that NIDA does not have an adequate supply has become significantly more apparent. NIDA has been unable to provide the strains requested for MAPS’ long-delayed Phase 2 clinical trial of smoked marijuana to treat symptoms of posttraumatic stress disorder (PTSD) in 76 U.S. veterans. As a result, the study is proceeding with lower potency marijuana than what MAPS researchers requested.

The DEA has previously claimed that U.S. international treaty obligations under the United Nations Single Convention on Narcotic Drugs (Single Convention) require a federal monopoly, but in April 2016, the State Department released a statement clarifying that the Single Convention does not in fact limit the number of U.S. marijuana producers.

Furthermore, the DEA’s 2009 rejection of the ALJ recommendation to license Craker relied heavily on a U.S. Department of Health and Human Services (HHS) protocol review process, which was eliminated in 2015.

MAPS’ upcoming Phase 2 clinical trial of marijuana for PTSD in veterans is in collaboration with investigators in Phoenix, Arizona, and at Johns Hopkins University, the University of Colorado, and the University of Pennsylvania. The study is funded by a $2.15 million grant to MAPS from the State of Colorado. The study has received full regulatory approval, and will be the first randomized controlled trial of whole plant marijuana as a treatment for PTSD.

Founded in 1986, MAPS is a non-profit research and educational organization working to evaluate the safety and efficacy of botanical marijuana as a potential prescription medicine for specific medical uses approved by the FDA.

MORE INFORMATION

Additional information can be found at maps.org/research/mmj/dea-license.

CONTACT:
Rick Doblin, Ph.D., MAPS Executive Director
rick@maps.org
617-276-7806

Natalie Ginsberg, MAPS Policy & Advocacy Manager
natalie@maps.org
917-520-5531

The above Press Release is courtesy of the Multidisciplinary Association for Psychedelic Studies (MAPS)  whose Mission Sates :

Mission

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Dr.William Courtney, discusses how a massive Inoperable Brain Tumor was remarkably reduced after the 8-month-old baby underwent treatment of Cannabis Oil placed on it’s pacifier.

Cannabis Oil helped an 8-month-old baby with an Inoperable Brain Tumor, said Dr.William Courtney during this taped interview with the Huffington Post.

The Parents “were putting Cannabinoid Oil on the baby’s pacifier twice a day, increasing the dose… And within two months there was a dramatic reduction”.

“Dr. Courtney pointed out that the success of the Cannabis approach means that “this child, because of that, is not going to have the long-term side effects that would come from a very high dose of chemotherapy or radiation“”.

Video is courtesy of the Lincoln Horsley YouTube channel

Click on this link to visit the Huffington Post website to read their article about this “Miracle Baby” which was titled “Cannabis For Infant’s Brain Tumor, Doctor Calls Child “A Miracle Baby”“.

Posted by Vincent Banial

 

Metabolically starving Cancer Cells through diet and compressed oxygen, replacing chemotherapy, surgery, or radiation is a therapy developed by Dr. Dominic D’Agostino

Dr. Dominic D’Agostino is an Assistant Professor at the University of South Florida College Of Medicine, Molecular Pharmacology & Physiology where he develops and tests Metabolic Therapies, including alternative energy substrates and ketogenic agents for neurological disorders, Cancer and wound healing.

While studying the effects of gasses on the brains of Navy Seal divers, he developed an approach for metabolically starving Cancer Cells through diet and compressed oxygen, replacing chemotherapy, surgery, or radiation.

Video is courtesy of the TEDx Talks YouTube channel

Click on this link to visit the official US Government PubMed site to view research findings published by Dr. Dominic D’Agostino titled “Press-pulse: a novel therapeutic strategy for the metabolic management of cancer.”

Click on this link to visit the official site of Dr. Dominic D’Agostino.

Posted by Vincent Banial

 

Northwestern researchers have discovered that when the human egg is activated by a sperm enzyme, an explosion of zinc sparks erupt


Northwestern University researchers have discovered that when the human egg is activated by a sperm enzyme, an explosion of zinc sparks erupt

If the videos do not start automatically, then click on the two  links below. They are from the study published in Scientific Reports

http://www.nature.com/article-assets/npg/srep/2016/160426/srep24737/extref/srep24737-s1.avi

http://www.nature.com/article-assets/npg/srep/2016/160426/srep24737/extref/srep24737-s2.avi

Video is courtesy of GeoBeats News YouTube channel

Abstract

Egg activation refers to events required for transition of a gamete into an embryo, including establishment of the polyspermy block, completion of meiosis, entry into mitosis, selective recruitment and degradation of maternal mRNA, and pronuclear development. Here we show that zinc fluxes accompany human egg activation. We monitored calcium and zinc dynamics in individual human eggs using selective fluorophores following activation with calcium-ionomycin, ionomycin, or hPLCζ cRNA microinjection. These egg activation methods, as expected, induced rises in intracellular calcium levels and also triggered the coordinated release of zinc into the extracellular space in a prominent “zinc spark.” The ability of the gamete to mount a zinc spark response was meiotic-stage dependent. Moreover, chelation of intracellular zinc alone was sufficient to induce cell cycle resumption and transition of a meiotic cell into a mitotic one. Together, these results demonstrate critical functions for zinc dynamics and establish the zinc spark as an extracellular marker of early human development.

Click on this line to visit the Northwestern University website page where this research is discussed.

Click on this line to visit the Scientific Reports website to read the complete study titled:

The zinc spark is an inorganic signature of human egg activation

Please note that there is download link at the above linked to Scientific Reports site, which allows you to download the full study report.

Title:
The zinc spark is an inorganic signature of human egg activation

Authors: Francesca E. Duncan, Emily L. Que, Nan Zhang, Eve C. Feinberg, Thomas V. O’Halloran et al.

Publication: Scientific Reports

Publisher: Nature Publishing Group

Date: Apr 26, 2016

Copyright © 2016, Rights Managed by Nature Publishing Group

Creative Commons

The article for which you have requested permission has been distributed under a Creative Commons CC-BY license (please see the article itself for the license version number). You may reuse this material without obtaining permission from Nature Publishing Group, providing that the author and the original source of publication are fully acknowledged, as per the terms of the license.
For license terms, please see http://creativecommons.org/

 

Posted by: Vincent Banial
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner.

If the Cancerous Tumor can be reached by thin optic fibers then this minimally invasive procedure could be an effective way to treat said Tumor

Getting any form of cancer can be life changing. The medical procedures used to eliminate the Cancer can also have life changing side effects.

Removing a Cancerous Prostate is one present way to deal with Colon Cancer.

There is a novel new procedure which has already been approved for use in Mexico. It may soon be approved for use in Europe.

The key part is that the procedure is minimally invasive. If the Cancerous Tumor can be reached by thin optic fibers then this procedure could be an effective way to treat said Tumor. The thin optic fiber is needed to direct the Laser light at the Tumor. “Laser light activation of an intravenous infusion of Tookad Soluble releases short-lived toxic oxygen and nitric oxide radicals that destroy the Cancer tumor’s blood vessels and thereby kill the tumorous cells”. The Tookad Soluble drug is eliminated from the body in less than 6 hours. Without the Laser Light activation the Tookad Soluble has no effect on other cells or organ. Ultra Sound is used to feed and direct the Optic Fibres into the patients body.

This new technology was developed by the Yeda Research and Development Company, of the Weizmann Institute in collaboration with Steba Biotech of Luxembourg. Steba Biotech received the license for Tookad Soluble from Yeda Research and Development Company.

Since this procedure can target Cancer Tumors where a Fibre Optic strand could reach the tumor, then the door may be open to treat many other forms of Cancer. More research and Clinical Studies are underway.

Click on this line to read much more detail about using Tookad Soluble activation via Laser Light to target Cancer Tumors.

Click on this line to visit the Times Of Israel news website to read their article on this procedure first developed by the Weizmann Institute.

 

 

Posted by: Vincent Banial
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice.

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model

I used to post about Medical Research in the past. For example, our prior post about research done at Harvard regarding the association between Heart Disease and microbial Human Gut Bacteria had researchers from around the globe visiting this site. Hey life is not just about great looking Exotic Cars, great looking Women and great sounding Music. You should add Medical Research to “round out” that mix.

This post is about research being conducted in Australia, which shows great promise in the treatment of Alzheimers. Apparently some memory loss could be reversed, in mice so far, by using their protocol and Scanning UltraSound.

The study was conducted by : Gerhard Leinenga and Jürgen Götz. Corresponding author. E-mail: j.goetz@uq.edu.au

Their study was published in the peer reviewed journal: Science Translational Medicine 11 Mar 2015: Vol. 7, Issue 278

The article was titled: Research Article Alzheimer’s Disease
Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model.

The following is the Abstract (posted for Educational purposes). A link is provided further down to access the complete text and a downloadable PDF.

Abstract

Amyloid-β (Aβ) peptide has been implicated in the pathogenesis of Alzheimer’s disease (AD). We present a nonpharmacological approach for removing Aβ and restoring memory function in a mouse model of AD in which Aβ is deposited in the brain. We used repeated scanning ultrasound (SUS) treatments of the mouse brain to remove Aβ, without the need for any additional therapeutic agent such as anti-Aβ antibody. Spinning disk confocal microscopy and high-resolution three-dimensional reconstruction revealed extensive internalization of Aβ into the lysosomes of activated microglia in mouse brains subjected to SUS, with no concomitant increase observed in the number of microglia. Plaque burden was reduced in SUS-treated AD mice compared to sham-treated animals, and cleared plaques were observed in 75% of SUS-treated mice. Treated AD mice also displayed improved performance on three memory tasks: the Y-maze, the novel object recognition test, and the active place avoidance task. Our findings suggest that repeated SUS is useful for removing Aβ in the mouse brain without causing overt damage, and should be explored further as a noninvasive method with therapeutic potential in AD.

Click on this line to view the complete text regarding the published results of this study.

Click on this line to view the entire article as a PDF or to Download a PDF copy of the Published material courtesy of the Science Translational Medicine site.

Click on this line to visit the official website of the Queensland Brain Institute at The University of Queensland Australia

Click on this line to visit the Clem Jones Centre for Ageing Dementia Research (CJCADR)

 

 

Posted by: Vincent Banial
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice. The Study Abstract has been included in this post for Educational Purposes and so is covered by the Fair Use component of Copyright. Uniquely Toronto makes no claims regarding the copyright or other rights to the published material. Also complete links have been included to the Science Translational Medicine site.

Fasting may have postive effects on Human Brains. This Ted Talk is presented by Neuroscientist Mark Mattson

A very interesting Ted Talk about the positive effects of fasting on the Brain. It is presented by Mark Mattson is the current Chief of the Laboratory of Neurosciences at the National Institute on Aging.

Video is courtesy of the TEDx Talks YouTube channel

From the research which Mark Mattson is undertaking, Fasting could benefit those suffering with Alzheimer’s Disease & Dementia.

As the number of Alzheimer’s Disease & Dementia patients spiral upwards, the research on Fasting could prove most important.

Posted by: Vincent Banial
www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner.

New Contagious form of Cancer discovered

Click n the link below to read the article posted on the Business Standard website, about a new Contagious for of Cancer which has been discovered.

http://mybs.in/2S2uNPj

Cancer is “very rarely” contagious. I believe that there exist only about 2 or 3 forms of cancer, which can survive the move from the original Host body to the Next Host body.

Posted by: Vincent Banial
www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice. Posting links is covered under the Fair Use Provision of Copyright. Permission was also granted by the Business Standard site to share their post link.

New Medical Study just published in the journal Cell: Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis

TMAlyase_GUT_graphical abstract_HAZEN-3Image is courtesy of the journal Cell which retains the Copyright and any and all other rights. Used with permission for educational purpose.

A new study just published in the peer reviewed journal Cell goes further into the research which we had posted about on Apil 08 2013. That 2013 post was titled : Intestinal microbiota metabolism producing Trimethylamine-N-Oxide (TMAO), may be a contributing factor in developing Cardiovascular Disease in Humans. That was an extremely important study which had been published in the peer reviewed journal Nature Medicine. Click on the previous line to read about that extremely important finding, as I believe that it presents a new foundation upon which we can potentially reverse Cardiovascular Disease in Humans.

The following are quotes about the new study from the journal Cell which was titled:
Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis

Highlights

•Gut microbial trimethylamine lyases are a therapeutic target for atherosclerosis
•3,3-dimethyl-1-butanol inhibits microbial trimethylamine formation
•3,3-dimethyl-1-butanol attenuates choline diet-enhanced atherosclerosis
•Non-lethal gut microbial enzyme inhibition can impact host cardiometabolic phenotypes

Summary

Trimethylamine (TMA) N-oxide (TMAO), a gut-microbiota-dependent metabolite, both enhances atherosclerosis in animal models and is associated with cardiovascular risks in clinical studies. Here, we investigate the impact of targeted inhibition of the first step in TMAO generation, commensal microbial TMA production, on diet-induced atherosclerosis. A structural analog of choline, 3,3-dimethyl-1-butanol (DMB), is shown to non-lethally inhibit TMA formation from cultured microbes, to inhibit distinct microbial TMA lyases, and to both inhibit TMA production from physiologic polymicrobial cultures (e.g., intestinal contents, human feces) and reduce TMAO levels in mice fed a high-choline or L-carnitine diet. DMB inhibited choline diet-enhanced endogenous macrophage foam cell formation and atherosclerotic lesion development in apolipoprotein e−/− mice without alterations in circulating cholesterol levels. The present studies suggest that targeting gut microbial production of TMA specifically and non-lethal microbial inhibitors in general may serve as a potential therapeutic approach for the treatment of cardiometabolic diseases.”

The authors and researchers of this new Study were:
Zeneng Wang, Adam B. Roberts, Jennifer A. Buffa, Bruce S. Levison, Weifei Zhu, Elin Org, Xiaodong Gu, Ying Huang, Maryam Zamanian-Daryoush, Miranda K. Culley, Anthony J. DiDonato, Xiaoming Fu, Jennie E. Hazen, Daniel Krajcik, Joseph A. DiDonato, Aldons J. Lusis and Stanley L. Hazen

Click on this line to visit the journal Cell website, which features the Full Text of this important newly published Study.

Click on this line to download the PDF of this new Study, from the Journal Cell’s website.

In laymen’s terms, this new Study (published in the journal Cell, showed that by lnhibiting the production of TMAO during the digestion process, clogging of arteries was vastly reduced in Mice. What worked in Mice could work in a similar manner in Humans. This study, in my opinion, adds a new layer to the very important knowledge foundation which was laid with the initial work published in the journal Nature Medicine (click here to view that post)

 

 

Posted by: Vincent Banial
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice. Neither Vincent Banial nor Uniquely Toronto make any claims to the copyright to the material discussed in the above post. Copyright is retained by the authors of the study and with the journal Cell.

This post is not meant to be medical advice. Always seek the help and advice of your on Medial Doctor. This post is strictly for “Educational Purposes”. Our initial post about TMAO (posted on April 08 2013 is one of our most popular posts. Students and researches from all around the globe have visited our site just to read that educational post.

Knowledge is power and I strive to give back to humanity, by posting information for educational purposes, such as this post.

This post is also licensed to share under the Creative Commons License

Attribution-NoDerivs
CC BY-ND

This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with Credit and Attribution to Vincent Banial.

An Aspirin a day could double survival chances of cancer sufferers

http://www.express.co.uk/life-style/health/608395/Cancer-survival-aspirin-a-day-pill-breast-heart-disease-Alzheimer-s-disease

Posted by: Vincent Banial for Uniquely Toronto
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice.

Brain implant could reverse memory loss in Alzheimers patients

http://www.express.co.uk/news/uk/609875/new-implant-reverse-Alzheimers-memory-loss-high-tech-device-treatment

Posted by: Vincent Banial for Uniquely Toronto
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. This post is subject to change without notice.

Neuroscientist Sara Lazar’s amazing brain scans show meditation can actually change the size of key regions of our brain, improving our memory and making us more empathetic, compassionate, and resilient under stress.

Video is courtesy of the TEDx Talks YouTube page

 

 

Posted by: Vincent Banial for Uniquely Toronto
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice.

Susan Cain discusses her book titled “Quiet. The Power of Introverts”

Introverts can be found in Human populations, in Animal populations and among Fish.

Susan Cain details some the extensive research about the differences between Human Extroverts and Human Introverts.

This fascinating video is thanks to Microsoft Research, which is the research division of Microsoft.

Video is courtesy of the UWTV YouTube Channel and Microsoft Research

Posted by: Vincent Banial for Uniquely Toronto
http://www.uniquelytoronto.com

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. This post is subject to change without notice.

New Medical Study: 38% of current antidepressant users never having met criteria for MDD, OCD, panic disorder, social phobia, or GAD; and 69% of current antidepressant users never having met the criteria for MDD in their lifetimes

The newly published medical study is titled “Antidepressant Use and Lifetime History of Mental Disorders in a Community Sample: Results From the Baltimore Epidemiologic Catchment Area Study“

Continue reading →

If you’re feeling Powerful and rather Confident, then you will be more likely to Cheat on your spouse


Powerful Men Cheat on their spouses. Powerful Women Cheat on their spouses. Researchers have found that there is a  correlation between the feeling of high confidence and the incidence of infidelity. People holding positions of power have high levels of confidence.

Continue reading →

Meditation might slow the age-related loss of gray matter in the brain per a new study by UCLA Researchers


A new study by UCLA researchers found that meditation appeared to help reduce the potential loss of the brain’s gray matter as people age.

The new UCLA Study was published in the recent issue of the online Swiss Journal titled “Frontiers in Psychology” in the “Cognition” section and part of the Research Topic Neuroimaging and Neuropsychology of Meditation states.

Areas of the brain affected by aging (in red) are fewer and less widespread in people who meditate, bottom row, than in people who don’t meditate.

Continue reading →

Hair Loss Treatment using Stem Cells, a BioMedical Breakthrough. Human Embryonic Stem Cells were directed to first generate Neural Crest cells and then hair-inducing Dermal Papillea like cells, which when transplanted under the skin induced “Robust Hair Growth”. Newly Published BioMedical Study lays the foundation for future Stem Cell based Hair Replacement Therapies.


Those suffering from Hair Loss have something potentially life changing to look forward to, thanks to a newly published BioMedical Study. titled: “Derivation of Hair-Inducing Cell from Human Pluripotent Stem Cells“.

Continue reading →

3D Printed Artificial Ears offer hope to children born with a congenital deformity called Microtia


Microtia/Anotia is a deformity of the external canal and middle ear which is not fully developed. It affects thousands of children born every year.

Continue reading →

New Harvard study, published in the May 9th Cell Journal, reveals that Growth Differentiation Factor 11 (GDF11) Protein is a Circulating Factor that can Reverse Age-Related Cardiac Hypertrophy in mice


Video courtesy Cellvideoabstracts and their YouTube Channel.

A study published by Cell Press May 9th (volume 153, issue4) in the journal Cell reveals that a blood hormone known as growth differentiation factor 11 (GDF11) declines with age, and old mice injected with this hormone experience a reversal in signs of cardiac aging.To view the press release from this ground breaking study please click on the following link: http://www.eurekalert.org/pub_releases/2013-05/cp-rhf050313.php.

You can purchase a copy of this study by clicking on the following link:  Science Direct – CELL Volume 153, Issue 4.

Related articles

Disclaimer: There could be unintentional errors or omissions in the above post. Always read the actual study abstract and purchase the study at the links included in this post. This post is not meant to be medical advice. I am not a licensed Medical Doctor. If you have an interest in this topic, then always discuss such medical issues, concerns and interests with your own licensed Medical Doctor or other licensed Medical Professional. No person, company or institution mentioned above are affiliated with this blog. No person, company or institution mentioned above has endorsed this blog or this post.